Goto-kakizaki rats: Its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus

Current Diabetes Reviews

Volumn 9, Issue 5, 2013, Pages 387-396

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

Diabetes mellitus; Diabetic nephropathy; GK rats; Glucose tolerance; Hyperglycemia; Insulin resistance; Islet inflammation; None obese animal model

Indexed keywords

ANGIOTENSINOGEN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; BENZYLAMINE; BIOTIN; EPOXIDE HYDROLASE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMEGLIMIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LEVACECARNINE; MAGNOLOL; METFORMIN; MITIGLINIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MORINGA OLEIFERA EXTRACT; NATEGLINIDE; NICOTINAMIDE; PYROGLUTAMIC ACID; REMOGLIFLOZIN ETABONATE; ROSIGLITAZONE; STEVIOSIDE; VANADIC ACID; VASCULOTROPIN; ZINC;

ADIPOSE TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE MODEL; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; FETUS DEVELOPMENT; GLOMERULOSCLEROSIS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GOTO KAKIZAKI RAT; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOTOXICITY; LONG TERM EXPOSURE; MESANGIUM CELL; MORINGA OLEIFERA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PERINATAL PERIOD; PLANT LEAF; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION;

ANIMALS; CELL COUNT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN-SECRETING CELLS; PREDIABETIC STATE; RATS; RATS, INBRED STRAINS;

EID: 84882770398     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/15733998113099990069     Document Type: Article

References (96)

1. Kumar S, Singh R, Vasudeva N, Sharma S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol. 2012; 11: 9.
2. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev. 2011; 7(5): 291-304.
3. Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 Receptor Antagonist: A new therapy for type 2 diabetes mellitus. J Pharm Sci. 2012; 101(5): 1647-1658.
4. Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013; 9(1): 25-53.
5. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in β-cell function. Nature. 2001; 414(6865): 788-791.
6. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes. 2004; 53(3): 624-632.
7. Ma ZA. The role of peroxidation of mitochondrial membrane phospholipids in pancreatic ß-cell failure. Curr Diabetes Rev. 2012; 8(1): 69-75.
8. Akash MSH, Rehman K, Sun H, Chen S. Assessment of release kinetics, stability and polymer interaction of PF127-based thermosensitive gel of IL-1Ra. Pharm Dev Technol. 2013; DOI:10.3109/10837450.2013775158.
9. Akash MSH, Rehman K, Li N, Gao JQ, Sun H, Chen S. Sustained delivery of IL-1Ra from Pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res. 2012; 29(12): 3475-3485.
10. Akash MSH, Rehman K, Gillani Z, Sun H, Chen S. Cross-species amino acids sequence comparison and computational docking of human IL-1Ra and rat IL-1Ra on rat receptor. J Proteomics Bioinform. 2013; 6(2): 38-42.
11. Akash MSH, Rehman K, Chen S. IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective. Pharm Res. 2013; DOI: 10.1007/s11095-013-1118-0.
12. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: An overview. Indian J Med Res. 2007; 125(3): 451-472.
13. Gupta D, Krueger CB, Lastra G. Over-nutrition, obesity and insulin resistance in the development of ß-cell dysfunction. Curr Diabetes Rev. 2012; 8(2): 76-83.
14. Rehman K, Akash MSH, Azhar S, et al. A Biochemical and Histopathologic Study Showing Protection and Treatment of Gentamicin-Induced Nephrotoxicity in Rabbits Using Vitamin C. Afr J Tradit Complement Altern Med. 2012; 9(3): 360-365.
15. Akash MSH, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Current Diabetes Rev. 2013; 9(4): 286-293.
16. Shafrir E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev. 1992; 8(3): 179-208.
17. Goto Y, Kakizaki M, Masaki N. Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc Jpn Acad. 1975; 51(1975): 80-85.
18. Ostenson CG, Efendic S. Islet gene expression and function in type 2 diabetes; studies in the Goto-Kakizaki rat and humans. Diabetes Obesity Metab. 2007; 9(Suppl 2): 180-186.
19. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007; 356(15): 1517-1526.
20. Ehses JA, Lacraz G, Giroix M, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA. 2009; 106(33): 13998-14003.
21. Edholm T, Cejvan K, Abdel-Halim SM, Efendic S, Schmidt PT, Hellström PM. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterol Motil. 2009; 21(3): 313-321.
22. Portha B, Giroix MH, Serradas, et al. β-Cell Function and Viability in the Spontaneously Diabetic GK Rat Information From the GK/Par Colony. Diabetes. 2001; 50(Suppl1): S89-S93.
23. Portha B. Programmed disorders of ß -cell development and function as one cause for type 2 diabetes? The GK rat paradigm. Diabetes Metab Res Rev. 2005; 21(6): 495-504.
24. Miralles F, Portha B. Early development of beta cells is impaired in the GK rat model of type 2 diabetes. Diabetes. 2001; 50(Suppl1): S84-S88.
25. Gu HF, Brismar K. Genetic association studies in diabetic nephropathy. Curr Diabetes Rev. 2012; 8(5): 336-344.
26. Jim B, Santos J, Spath F, Cijiang He J. Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev. 2012;8(5): 317-328.
27. Movassat J, Bailbe D, Lubrano-Berthelier C, et al. Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am J Physiol Endocrinol Metab. 2008; 294(1): E168-E175.
28. Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013; 114(3): 525-531.
29. Donath MY, Böni-Schnetzle M, Ellingsgaard H, Ehses JA. Islet Inflammation Impairs the Pancreatic ß-Cell in Type 2 Diabetes. Physiology. 2009; 24(6): 325-331.
30. Portha B, Lacraz G, Dolz M, Homo-Delarche F, Giroix MH, Movassat J. Defective functional ß-cell mass and type 2 diabetes in the Goto-kakizaki rat model. Expert Rev Endocrinol Metab. 2007; 2(6): 785-795.
31. Movassat J, Portha B. Beta-cell growth in the neonatal Goto-Kakizaki rat and regeneration after treatment with streptozotocin at birth. Diabetologia. 1999; 42(9): 1098-1106.
32. Movassat J, Saulnier C, Serradas P, Portha B. Impaired development of pancreatic β-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia. 1997; 40(8): 916-925.
33. Ling ZC, Hong-lie C, Ostenson CG, Efendic S, Khan A. Hyperglycemia contributes to impaired insulin response in GK rats islets. Diabetes. 2001; 50(Suppl1): 108-112.
34. Weijers RN. Lipid composition of cell membranes and its relevance in type 2 diabetes mellitus. Curr Diabetes Rev. 2012; 8(5): 390-400.
35. Homo-Delarche F, Calderari S, Irminger JC, et al. Islet Inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes. 2006; 55(6): 1625-1633.
36. Portha B, Lacraza G, Kergoatb M, et al. The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol. 2009; 297(1-2): 73-85.
37. Lacraz G, Giroix MH, Kassis N, et al. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the Type 2 diabetic GK rat. PLoS One. 2009; 4(9): e6963.
38. Guenifi A, Abdel-Halim SM, Höög A, Falkmer S, Ostenson CG. Preserved beta-cell density in the endocrine pancreas of young, spontaneously diabetic Goto-Kakizaki (GK) rats. Pancreas. 1995; 10(2): 148-153.
39. Serradas P, Gangnerau MN, Giroix MH, Saulnier C, Portha B. Impaired pancreatic beta cell function in the fetal GK rat. Impact of diabetic inheritance. J Clin Invest. 1998; 101(4): 899-904.
40. Boloker J, Gertz SJ, Simmons RA. Gestational diabetes leads to the development of diabetes in adulthood in the rat. Diabetes. 2002; 51(5): 1499-1506.
41. Sato N, Komatsu K, Kurumatani H. Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol. 2003; 23(5): 334-342.
42. Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev. 2011; 7(1): 41-49.
43. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab. 2005; 7(4): 307-317.
44. Boerner BP, Shivaswamy V, Desouza CV, Larsen JL. Diabetes and cardiovascular disease following kidney transplantation. Curr Diabetes Rev. 2011; 7(4): 221-234.
45. Nakamura S, Makita Z, Ishikawa S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 1997; 46(5): 895-899.
46. Van Buren PN, Toto R. Current update in the management of diabetic nephropathy. Curr Diabetes Rev. 2013; 9(1): 62-77.
47. Phillips AO, Baboolal K, Riley S, et al. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin dependent diabetes mellitus. Am J Kidney Dis. 2001; 37(2): 400-410.
48. Mauer S, Steffes M, Ellis E, Sutherland D, Brown D, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984; 74(4): 1143-1155.
49. Lacraz G, Figeac F, Movassat J, et al. Diabetic ß-cells can achieve self-protection against oxidative stress through an adaptative upregulation of their antioxidant defenses. Lesson from the diabetic GK/Par rat. PLoS One. 2009; 4(8): e6500.
50. Lacraz G, Figeac F, Movassat J, Kassis N, Portha B. Diabetic GK/Par rat ß-cells are spontaneously protected against H2O2-triggered apoptosis. A cAMP-dependent adaptive response. Am J Physiol Endocrinol Metab. 2010; 298(1): E17-E27.
51. Ihara Y, Toyokuni S, Uchida K, et al. Hyperglycemia causes oxidative stress in pancreatic β-cells of GK rats, a model of type 2 diabetes. Diabetes. 1999; 48(4): 927-932.
52. Akash MSH, Rehman K, Rasool F, et al. Alternate therapy of type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J Med Plants Res. 2011; 5(31): 6885-6889.
53. Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet cell. Free Radic Biol Med. 2006; 4192): 177-184.
54. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009; 5(2):120-44.
55. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2): 98-107.
56. Suzuki N, Aizawa T, Asanuma N, et al. An early insulin intervention accelerates pancreatic β-Cell dysfunction in young Goto-Kakizaki rats, a model of naturally occurring noninsulin-dependent diabetes. Endocrinology. 1997; 138(3): 1106-1110.
57. Khan A, Chandramouli V, Ostenson CG, et al. Evidence for the presence of glucose cycling in pancreatic islets of the ob/ob mouse. J Biol Chem. 1989; 264(17): 9732-9733.
58. Zaitsev S, Efanova I, Ostenson CG, Efendic S, Berggren PO. Delayed Ca2 β response to glucose in diabetic GK rat. Biochem Biophys Res Commun. 1997; 239(1): 129-133.
59. Dadke SS, Li HC, Kusari AB, Begum N, Kusari J. Elevated expression and activity ofprotein-tyrosine phosphatise 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats. Biochem Biophys Res Commun. 2000; 274(3): 583-589.
60. Rehman K, Chen Z, Wang WW, et al. Mechanisms underlying the inhibitory effects of arsenic compounds on protein tyrosine phosphatase (PTP). Toxicol Appl Pharm. 2012; 263(3): 273-280.
61. Hao J, Shen W, Sun L, et al. Mitochondrial dysfunction in the liver of type 2 diabetic Goto-Kakizaki rats: improvement by a combination of nutrients. Br J Nutr. 2011; 106(5): 648-655.
62. Picarel-Blanchot F, Berthelier C, Bailbe D, Portha B. Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rats. Am J Physiol. 1996; 271(4 pt 1): E755-E762.
63. Sena CM, Barosa C, Nunes E, Seica R, Jones JG. Sources of endogenous glucose production in Goto kakizaki diabetic rat. Diabetes Metab. 2007; 33(4): 296-302.
64. Tsuura Y, Ishida H, Okamoto Y, et al. Glucose sensitivity of ATPsensitive K+ channels is impaired in β -cells of the GK rat. Diabetes. 1993; 42(10): 1446-1453.
65. Ostenson CG, Khan A, Abdel-Halim SM, et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia. 1993; 36(1): 3-8.
66. Ling ZC, Efendic S, Wibom R, Abdel-Halim SM, Ostenson CG, Landau BR, Khan A. Glucose metabolism in Goto-Kakizaki rat islets. Endocrinology. 1998; 139(6): 2670-2675.
67. Ostenson CG, Abdel-Halim SM, Rasschaert J, et al. Deficient activity of FAD-linked glycerophosphate dehydrogenase in islets of GK rats. Diabetologia. 1993; 36(8): 722-726.
68. MacDonald MJ, Efendic S, Ostenson CG. Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rat. Diabetes. 1996; 45(7): 886-890.
69. Ostenson CG, Chen J, Sheu L, Gaisano HY. Effects of palmitate on insulin secretion and exocytotic proteins in islets of diabetic GK rats. Pancreas. 2007; 34(3): 359-363.
70. Kowluru A. Emerging roles for protein histidine phosphorylation in cellular signal transduction: Lesson from islet beta-cell. J Cell Mol Med. 2008; 12(5B): 1885-1908.
71. Mosen H, Salehi A, Alm P, et al. Defective Glucose-Stimulated Insulin Release in the Diabetic Goto-Kakizaki (GK) Rat Coincides with Reduced Activity of the Islet Carbon Monoxide Signaling Pathway. Endocrinology. 2005; 146(3): 1553-1558.
72. Derakhshan F, Toth C. Insulin and the Brain. Curr Diabetes Rev. 2013; 9(2): 102-116.
73. Wiseman DA, Thurmond DC. The good and bad effects of cysteine S-nitrosylation and tyrosine nitration upon insulin exocytosis: a balancing act. Curr Diabetes Rev. 2012; 8(4): 303-315.
74. Dinarello CA. Blocking interleukin-1 β in acute and chronic autoinflammatory diseases. J Intern Med. 2011; 269(1): 16-28.
75. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev. 2005; 1(1): 59-63.
76. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes from metabolic stress to therapy. Diabetes. 2008; 31(Suppl 2): S161-S164.
77. Sohn EJ, Kim CS, Kim YS, et al. Effects of magnolol (5,5 β-diallyl-2,2 β-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci. 2007; 80(5): 468-475.
78. Akash MSH, Rehman K, Sun H, Chen S. IL-1Ra improves normoglycemia and insulin sensitivity in diabetic GK-Rats. Eur J Pharmacol. 2013; 701(1-3): 87-95.
79. Akash MSH, Rehman K, Sun H, Chen S. Sustained delivery of IL-1Ra from PF127 gel reduces hyperglycemia in diabetic GK-rats. PloS One. 2012; 8(2): e55925.
80. Gao W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011; 336(3): 881-890.
81. Abella A, Marti L, Camps M, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-kakizaki rats. Diabetes. 2003; 52(4): 1004-1013.
82. Iizuka Y, Sakurai E, Tanaka Y. Antidiabetic effect of Folium Mori in GK Rats. Yakugaku Zasshi. 2001; 121(5): 365-369.
83. Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin-A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes. J Diabetes Metab. 2011; 2(4): 126.
84. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (sglt2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008; 327(1): 268-276.
85. Kawai J, Ohara-Imaizumi M, Nakamichi Y, et al. Insulin exocytosis in Goto-Kakizaki rat β-cells subjected to long-term glinide or sulfonylurea treatment. Biochem J. 2008; 412(1): 93-101.
86. Nagamatsu S, Ohara-Imaizumi M, Nakamichi Y, Kikuta T, Nishiwaki C. Imaging Docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules. Diabetes. 2006; 55(10): 2819-2825.
87. Louro TM, Matafome PN, Nunes EC, da Cunha FX, Seiça RM. Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol. 2011; 653(1-3): 89-94.
88. Jeppesen PB, Gregersen S, Alstrup KK, Hermansen K. Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine. 2002; 9(1): 9-14.
89. Yada T, Sakurada M, Filipsson K, Kikuchi M, Ahren B. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci. 2000; 921:259-263.
90. Yan J, Feng Z, Liu J, et al. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)-epigallocatechin-3-gallate. J Nutr Biochem. 2012; 23(7): 716-724.
91. Yoshinari O, Igarashi K. Anti-diabetic effects of pyroglutamic acid in type 2 diabetic Goto-Kakizaki rats and KK-Ay mice. Br J Nutr. 2011; 106(7): 995-1004.
92. Song MK, Hwang IK, Rosenthal MJ, et al. Antidiabetic actions of arachidonic acid and zinc in genetically diabetic Goto-Kakizaki rats. Metabolism. 2003; 52(1): 7-12.
93. Yoshinari O, Sato H, Igarashi K. Anti-diabetic effects of pumpkin and its constituents, trigonelline and nicotinic acid on goto-kakizaki rats. Biosci Biotechnol Biochem. 2009; 73(5): 1033-1041.
94. Ndong M, Uehara M, Katsumata S, Suzuki K. Effects of oral administration of moringa oleifera lam on glucose tolerance in goto-kakizaki and wistar rats. J Clin Biochem Nutr. 2007; 40(3): 229-233.
95. Shen W, Hao J, Tian C, et al. A Combination of Nutriments Improves Mitochondrial Biogenesis and Function in Skeletal Muscle of Type 2 Diabetic Goto-Kakizaki Rats. PLoS One. 2008; 3(6): e2328.
96. Gao W, Jusko W. Modeling disease progression and rosiglitazone intervention in type 2 diabetic goto-kakizaki rats. J Pharmacol Exp Ther. 2012; 341(3): 617-625.